Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Biogen (BIIB) PT Raised to $292 at RBC Capital

August 2, 2024 6:24 AM EDT

RBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.

The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More

Biogen (BIIB) tops Q2 expectations, raises profit guidance

August 1, 2024 7:27 AM EDT

Biogen (NASDAQ: BIIB) reported its second-quarter results on Thursday, surpassing analyst expectations with an adjusted EPS of $5.28, significantly higher than the estimated $4.01.

The company's revenue also exceeded forecasts, coming in at $2.47 billion against a consensus estimate of $2.39 billion. Despite a flat year-over-year (YoY) total revenue, the adjusted EPS saw a notable 31% increase YoY.

The pharmaceutical giant's strong performance is reflected in its raised full-year... More